SELLAS Life Sciences
Single-asset biotech — binary catalyst risk, keep separate from the TEM/CRSP quality-biotech bucket.
$8.42
+6.85%
Short interest
Short % of float
26.9%
Days to cover
11.9d
Shares short
53.76M
Vs Sep 15
-9%
Crowded short. If this turns, covering has to buy a large slice of the float.
Why it's this high: up 420% over the past year and now 47% off the 52-week high, down 24% this quarter. Shorts are sitting on that giveback — the usual bet is that the spike does not fully hold. Days to cover are high, so a turn forces them to keep buying for several sessions.
Fundamentals-driven short
Revenue, margin, debt, or FCF trend is weak here — this reads more like shorts betting against real business risk than a crowded contrarian squeeze.
Share count and days to cover are the latest FINRA settlement. Short % of float is from Finviz. Prints land about twice a month — fuel for a turn, not today's flow.
SLS Q3 earnings
Check guidance — raised = hold; lowered = review thesis
No recent news
No upcoming earnings date on the calendar
Last reported · 2026-06-30
Last surprise -9.9% vs estimate
Calendar earnings dates
SLS Q3 earnings
Check guidance — raised = hold; lowered = review thesis
Insider trades (Form 4)
Buys
1,978,400 sh
$16.1M
Sells
309,458 sh
$500K
Net (12 filings)
+1,668,942 sh
+$15.6M net
Stergiou Angelos M. (Stock award / grant) — 1,065,000 sh · $9.0M
Varian John (Stock award / grant) — 50,000 sh · $0.4M
CICIC DRAGAN (Stock award / grant) — 300,000 sh · $2.5M
Burns John Thomas (Stock award / grant) — 300,000 sh · $2.5M
Kalin Katherine Bach (Stock award / grant) — 50,000 sh · $0.4M
Wasman Jane (Stock award / grant) — 50,000 sh · $0.4M
SCHEINBERG DAVID A (Stock award / grant) — 50,000 sh · $0.4M
VAN NOSTRAND ROBERT L (Stock award / grant) — 50,000 sh · $0.4M
CICIC DRAGAN (Form 4 transaction) — 63,800 sh · $0.1M
Burns John Thomas (Form 4 transaction) — 58,592 sh · $0.1M
Stergiou Angelos M. (Form 4 transaction) — 187,066 sh · $0.3M
Kalin Katherine Bach (Open-market purchase) — 63,400 sh · $0.1M
SLS Q2 2026 earnings (est.)
Estimated — verify before trading
RSI, moving averages, MACD, Bollinger bands & candlestick patterns from Yahoo daily data — verify on chart
Below 20-day MA
Price $8.42 vs 20 SMA $10.58
Below 50-day MA
Price $8.42 vs 50 SMA $11.56
Below 200-day MA
Price $8.42 vs 200 SMA $8.68
Below 251-day high
-45.5% from 251-day high ($15.46)
Above 251-day low
505.8% above 251-day low ($1.39)
Hammer
Long lower wick on 2026-11-06 — potential reversal
Gap up
Opened 1.9% above prior close on 2026-11-06
Price vs 200-day EMA, plus whether profit shows up as cash. Cash flow, cash, capex growth, and interest coverage sit next to the multiple.
7.0% below 200-day EMA
Growth, margin, debt or FCF trend is weak — a cheap price here may be a value trap, not a discount.
Trailing PE
—
Invest rank
25
Swing rank
50
Earnings skew
open
Cash flow/share
−$0.36
Trailing twelve months
Cash/share
$0.69
Latest quarter
Interest cover
-238.6x
Operating profit / interest
Price / FCF
—
After capex
Rev / share
—
Five-year revenue growth per share
Capex growth
—
5-year rate
Gross margin
93.1%
Prior year 90.0%
Revenue growth
—
YoY, TTM or latest quarter
Net margin
-736.2%
TTM profitability
Debt / equity
0.0%
Lower = less leveraged
FCF growth
—
5Y CAGR, capex-aware
Composite fundamentals score: 28/100 · from Finnhub basic financials, verify against the latest 10-Q before acting.